At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
GSK2402968 3mg/kg/week +3 moredrug
Likely dose
GSK2402968 3mg/kg/weekfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Study to Assess Two Doses of GSK2402968 in the Treatment of Ambulant Boys With Duchenne Muscular Dystrophy
In Brief
A Phase 2 clinical trial evaluating GSK2402968 3mg/kg/week, GSK2402968 6 mg/kg/week, and 2 other interventions for Muscular Dystrophies. Completed, enrolled 51 participants across 14 sites.
Detailed Summary
The purpose of this study is to determine if GSK2402968 is effective in the treatment of ambulant boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping. Two doses of GSK2402968 and placebo will be used in this study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMuscular Dystrophies
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedOct 2011
Primary CompletionMay 2013
Study CompletionNov 2013
TodayJul 2026
First PostedOct 31, 2011
Enrollment StartOct 26, 2011
Primary CompletionMay 21, 2013
Study CompletionNov 4, 2013
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 14.7 years ago
Interventions
GSK2402968 3mg/kg/weekdrug
Comparison of 2 doses of GSK2402968
GSK2402968 6 mg/kg/weekdrug
Comparison of 2 doses of GSK2402968
Placebo to match GSK2402968 3 mg/kg/weekdrug
Matched placebo
Placebo to match GSK2402968 6 mg/kg/weekdrug
Matched Placebo